The closing price of Syndax Pharmaceuticals Inc (NASDAQ: SNDX) was $21.28 for the day, down -1.57% from the previous closing price of $21.62. On the day, 749097 shares were traded.
Ratios:
Our analysis of SNDX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 10.00 and its Current Ratio is at 10.00. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Scotiabank on January 31, 2024, Downgraded its rating to Sector Perform and sets its target price to $23 from $36 previously.
On December 22, 2023, Mizuho started tracking the stock assigning a Buy rating and target price of $45.
On October 25, 2023, BofA Securities started tracking the stock assigning a Buy rating and target price of $29.BofA Securities initiated its Buy rating on October 25, 2023, with a $29 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 09 ’23 when Morrison Briggs sold 52,855 shares for $18.27 per share. The transaction valued at 965,402 led to the insider holds 17,836 shares of the business.
Meury William sold 83,000 shares of SNDX for $1,697,810 on Aug 02 ’23. The Director now owns 48,000 shares after completing the transaction at $20.46 per share. On Jul 10 ’23, another insider, Morrison Briggs, who serves as the Director of the company, sold 52,855 shares for $20.40 each. As a result, the insider received 1,078,068 and left with 17,836 shares of the company.
Stock Price History:
Over the past 52 weeks, SNDX has reached a high of $25.34, while it has fallen to a 52-week low of $11.22.
Shares Statistics:
A total of 84.83M shares are outstanding, with a floating share count of 80.62M. Insiders hold about 5.11% of the company’s shares, while institutions hold 100.48% stake in the company.
Earnings Estimates
The firm’s stock currently is rated by NASDAQ 100 analysts. The consensus estimate for the next quarter is $1.98, with high estimates of $18.94 and low estimates of $0.47.
Analysts are recommending an EPS of between $Communication Services and $Healthcare for the fiscal current year, implying an average EPS of $Consumer Defensive. EPS for the following year is $Stocks, with Index analysts recommending between $Stocks and $Stocks.
